MAY 15 2006
PATENT & TRADEMARK OFFICE

SEQUENCE LISTING

<110> FINDEIS, MARK A.
GEFTER, MALCOLM L.
MUSSO, GARY
SIGNER, ETHAN R.
WAKEFIELD, JAMES
MOLINAUX, SUSAN
CHIN, JOSEPH
LEE, JUNG-JA
KELLEY, MICHAEL
KOMAR-PANICUCCI, SONJA
ARICO-MUENDEL, CHRISTOPHER C.
PHILLIPS, KATHRYN
HAYWARD, NEIL J.

<120> MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION
COMPRISING D-AMINO ACIDS

<130> PPI-0016CP4CN3

<140> 10/677,076
<141> 2003-09-30

<150> 09/895,443
<151> 2001-06-29

<150> 09/356,931
<151> 1999-07-19

<150> 08/920,162
<151> 1997-08-27

<150> 08/548,998
<151> 1995-10-27

<150> 08/616,081
<151> 1996-03-14

<150> 08/703,675
<151> 1996-08-27

<150> 08/897342
<151> 1997-07-21

<160> 37

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 43
<212> PRT
<213> Homo sapiens

<400> 1

Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln	Lys
1				5					10					15	

Leu	Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile	Ile
		20					25					30			

JIPE

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr
35 40

<210> 2
<211> 103
<212> PRT
<213> Homo sapiens

<400> 2
Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
1 5 10 15

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
20 25 30

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
35 40 45

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile
50 55 60

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg
65 70 75 80

His Leu Ser Lys Met Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
85 90 95

Phe Phe Glu Gln Met Gln Asn
100

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 3
Leu Val Phe Phe Ala
1 5

<210> 4
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 4
Ala Phe Phe Val Leu
1 5

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 5
Ala Phe Phe Leu Leu
 1   5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 6
Leu Phe Phe Val Leu
 1   5

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 7
Phe Phe Phe Val Leu
 1   5

<210> 8
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<400> 8
Leu Val Phe Phe
 1

<210> 9
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<400> 9
Leu Val Phe Phe
 1

<210> 10
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(3)
<223> Modified site, D amino acid

<220>
<221> MOD_RES
<222> (3)
<223> phenethylamide C-terminal modification

<400> 10
Leu Val Phe
 1

<210> 11
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<400> 11
Leu Val Tyr Phe
 1

<210> 12
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<220>
<221> MOD_RES
<222> (3)
<223> iodotyrosine

<400> 12
Leu Val Xaa Phe
 1

<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<400> 13
Leu Val Phe Tyr
 1

<210> 14
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES

<222> (4)
<223> iodotyrosine

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<400> 14
Leu Val Phe Xaa
 1

<210> 15
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<400> 15
Leu Val Phe Ala
 1

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<400> 16
Leu Val Phe Phe Ala
 1   5

<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 17
Ala Val Phe Phe Leu
1 5

<210> 18
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 18
Leu Val Tyr Phe Ala
1 5

<210> 19
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (3)
<223> iodotyrosine

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 19
Leu Val Xaa Phe Ala
1 5

<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 20

Leu Val Phe Tyr Ala
1 5

<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (4)
<223> iodotyrosine

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 21
Leu Val Phe Xaa Ala
1 5

<210> 22
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<400> 22
Phe Phe Val Leu
1

<210> 23
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(4)
<223> Modified site, D amino acid

<400> 23
Ala Phe Phe Val
1

<210> 24
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 24
Phe Phe Phe Leu Val
 1   5

<210> 25
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 25
Phe Phe Phe Phe Leu
 1   5

<210> 26
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 26
Ala Phe Phe Phe Leu
 1   5

<210> 27
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 27
Leu Val Phe Phe Phe
 1   5

<210> 28
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 28
Leu Val Phe Phe Val

 1   5

<210> 29
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 29
Leu Val Tyr Tyr Ala
 1   5

<210> 30
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)

<223> Modified site, D amino acid

<400> 30
Leu Phe Phe Phe Leu
 1   5

<210> 31
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<220>
<221> MOD_RES
<222> (5)
<223> Adp modification

<400> 31
Asp Asp Ile Ile Leu
 1   5

<210> 32
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> VARIANT
<222> (1)..(5)
<223> Modified site, D amino acid

<400> 32
Leu Val Tyr Phe Ala
 1   5

<210> 33
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (1)
<223> cholyl modification

<220>
<221> MOD_RES
<222> (5)
<223> amide modification

<400> 33
Leu Val Phe Phe Ala
1 5

<210> 34
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (1)
<223> cholyl modification

<220>
<221> MOD_RES
<222> (5)
<223> hydroxyl modification

<400> 34
Leu Val Phe Phe Ala
1 5

<210> 35
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (1)
<223> hyodeoxycholyl modification

<220>
<221> MOD_RES
<222> (5)
<223> hydroxyl modification

<400> 35
Leu Val Phe Phe Ala
1 5

<210> 36
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (1)
<223> chenodeoxycholyl modification

<220>
<221> MOD_RES
<222> (5)
<223> hydroxyl modification

<400> 36
Leu Val Phe Phe Ala
 1   5

<210> 37
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (1)
<223> ursodeoxycholyl modification

<220>
<221> MOD_RES
<222> (5)
<223> hydroxyl modification

<400> 37
Leu Val Phe Phe Ala
 1   5